Eli Lilly's Zepbound reduces type 2 diabetes risk, study shows

Shares of Eli Lilly jumped Tuesday after a study showed its blockbuster weight-loss drug significantly reduced the risk of overweight patients developing type 2 diabetes. Results from a recent trial showed weekly shots of tirzepatide injections significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity compared to the placebo, according to the pharmaceutical giant. The treatment with the drug, currently sold under the brand names Zepbound and Mounjaro, ...